News | January 05, 2023
Yaral Pharma launches diclofenac epolamine topical system 1.3%
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Having a healthy gut is key as it permits the body to build a stronger immune system
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
The new facility will be able to handle four times as many patients as the previous facility.
Subscribe To Our Newsletter & Stay Updated
